These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33419247)

  • 21. Beneficial effects of C-peptide on renal morphology in diabetic rats.
    Sun W; Gao X; Zhao X; Cui D; Xia Q
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):893-9. PubMed ID: 21106770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+-K+-ATPase alpha1-subunit in rats.
    Nordquist L; Shimada K; Ishii T; Furuya DT; Kamikawa A; Kimura K
    Diabetes Metab Res Rev; 2010 Mar; 26(3):193-9. PubMed ID: 20225182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of C-peptide on diabetic nephropathy: A review of molecular mechanisms.
    Yaribeygi H; Maleki M; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Nov; 237():116950. PubMed ID: 31605709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.
    Wahren J; Foyt H; Daniels M; Arezzo JC
    Diabetes Care; 2016 Apr; 39(4):596-602. PubMed ID: 26884473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-peptide and diabetic kidney disease.
    Brunskill NJ
    J Intern Med; 2017 Jan; 281(1):41-51. PubMed ID: 27640884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.
    Oguiza A; Recio C; Lazaro I; Mallavia B; Blanco J; Egido J; Gomez-Guerrero C
    Diabetologia; 2015 Jul; 58(7):1656-67. PubMed ID: 25982245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-peptide corrects hepatocellular dysfunction in a rat model of type 1 diabetes.
    Abdel-Hamid HA; Abdel-Hakeem EA; Zenhom NM; Toni NDM
    J Physiol Biochem; 2020 Aug; 76(3):417-425. PubMed ID: 32529526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus.
    Kunt T; Schneider S; Pfützner A; Goitum K; Engelbach M; Schauf B; Beyer J; Forst T
    Diabetologia; 1999 Apr; 42(4):465-71. PubMed ID: 10230651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic potential of VEGF inhibition in diabetic microvascular complications.
    Tremolada G; Lattanzio R; Mazzolari G; Zerbini G
    Am J Cardiovasc Drugs; 2007; 7(6):393-8. PubMed ID: 18076206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism.
    Liang G; Song L; Chen Z; Qian Y; Xie J; Zhao L; Lin Q; Zhu G; Tan Y; Li X; Mohammadi M; Huang Z
    Kidney Int; 2018 Jan; 93(1):95-109. PubMed ID: 28750927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of inflammatory and vascular endothelial dysfunction biomarkers in microvascular and macrovascular complications in type 1 diabetes.
    Wołoszyn-Durkiewicz A; Myśliwiec M
    Pediatr Endocrinol Diabetes Metab; 2019; 25(1):28-35. PubMed ID: 31343130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.
    Huang KC; Cherng YG; Chen LJ; Hsu CT; Cheng JT
    Horm Metab Res; 2014 Apr; 46(4):240-4. PubMed ID: 24136780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphological changes in the sciatic nerve of diabetic rats treated with low molecular weight heparin OP 2123/parnaparin.
    Artico M; Massa R; Cavallotti D; Franchitto S; Cavallotti C
    Anat Histol Embryol; 2002 Aug; 31(4):193-7. PubMed ID: 12196260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.
    Sima AA; Zhang W; Sugimoto K; Henry D; Li Z; Wahren J; Grunberger G
    Diabetologia; 2001 Jul; 44(7):889-97. PubMed ID: 11508275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.
    Malik S; Suchal K; Khan SI; Bhatia J; Kishore K; Dinda AK; Arya DS
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F414-F422. PubMed ID: 28566504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
    Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
    Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy.
    Gupta A; Behl T; Sehgal A; Bhatia S; Jaglan D; Bungau S
    Mol Biol Rep; 2021 Mar; 48(3):2761-2774. PubMed ID: 33754251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-peptide makes a comeback.
    Wahren J; Jörnvall H
    Diabetes Metab Res Rev; 2003; 19(5):345-7. PubMed ID: 12951641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
    Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M
    Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.
    Ido Y; Vindigni A; Chang K; Stramm L; Chance R; Heath WF; DiMarchi RD; Di Cera E; Williamson JR
    Science; 1997 Jul; 277(5325):563-6. PubMed ID: 9228006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.